TY - JOUR
T1 - Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
AU - Rotow, Julia
AU - Patel, Jyoti D.
AU - Hanley, Matthew P.
AU - Yu, Helena
AU - Awad, Mark
AU - Goldman, Jonathan W.
AU - Nechushtan, Hovav
AU - Scheffler, Matthias
AU - Kuo, Chih Hsi S.
AU - Rajappa, Senthil
AU - Harada, Guilherme
AU - Clifford, Sarah
AU - Santucci, Alison
AU - Silva, Laura
AU - Tupper, Rebecca
AU - Oxnard, Geoffrey R.
AU - Kherani, Jennifer
AU - Drilon, Alexander
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/8/15
Y1 - 2023/8/15
N2 - Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion-mediated osimertinib resistance has not previously been published. Patients and Methods: Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected. Results: Fourteen patients with EGFR-mutant and RET fusion-positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusions (CCDC6-RET 50%, NCOA4-RET 36%) predominated. Osimertinib 80 mg daily and selpercatinib 80 mg twice daily were the most commonly administered dosages. The response rate, disease control rate, and median treatment duration were 50% [95% confidence interval (CI), 25%-75%, n ¼ 12], 83% (95% CI, 55%-95%), and 7.9 months (range, 0.8-25þ), respectively. Resistance was complex, involving EGFR on-target (EGFR C797S), RET on-target (RET G810S), and off-target (EML4-ALK/STRN-ALK, KRAS G12S, BRAF V600E) mechanisms; RET fusion loss; or polyclonal mechanisms. Conclusions: For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible and safe and offered clinical benefit, supporting the prospective evaluation of this combination.
AB - Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion-mediated osimertinib resistance has not previously been published. Patients and Methods: Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected. Results: Fourteen patients with EGFR-mutant and RET fusion-positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusions (CCDC6-RET 50%, NCOA4-RET 36%) predominated. Osimertinib 80 mg daily and selpercatinib 80 mg twice daily were the most commonly administered dosages. The response rate, disease control rate, and median treatment duration were 50% [95% confidence interval (CI), 25%-75%, n ¼ 12], 83% (95% CI, 55%-95%), and 7.9 months (range, 0.8-25þ), respectively. Resistance was complex, involving EGFR on-target (EGFR C797S), RET on-target (RET G810S), and off-target (EML4-ALK/STRN-ALK, KRAS G12S, BRAF V600E) mechanisms; RET fusion loss; or polyclonal mechanisms. Conclusions: For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible and safe and offered clinical benefit, supporting the prospective evaluation of this combination.
UR - http://www.scopus.com/inward/record.url?scp=85168791110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168791110&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-2189
DO - 10.1158/1078-0432.CCR-22-2189
M3 - Article
C2 - 36996322
AN - SCOPUS:85168791110
SN - 1078-0432
VL - 29
SP - 2979
EP - 2987
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -